Targets › AXL
6 programs from 6 companies in 29 trials: 16 Phase 1, 7 Phase 2, 6 Phase 3; Oncology, Respiratory; next expected readout Dec 2026.
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factors GAS6 and PROS1, and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, AXL binds and induces…. (UniProt, P30530)
Open in Phaseline: the race on AXL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Bemcentinib Tyrosine-protein kinase receptor UFO inhibitor | AXL | Phase 3 | Head & Neck Squamous Cell Carcinoma | Mar 2028 |
| Beijing Scitech-Mq Pharmaceuticals | ST-1898 Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI | VEGFR2, MET, AXL, PDGFRA, RET | Phase 2 | Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell Carcinoma | Dec 2026 |
| Xuanzhu Biopharmaceutical | XZB-0004 AXL receptor tyrosine kinase inhibitor | AXL | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| Jonsson Comprehensive Cancer Center | AB801 AXL inhibitor | AXL | Phase 1 | Borderline Resectable Pancreatic Ductal Adenocarcinoma | Jun 2027 |
| Qurient | Adrixetinib (Q702) Axl/Mer/CSF1R selective tyrosine kinase inhibitor | AXL, MER, CSF1R | Phase 1 | Esophageal Cancer; Chronic Graft-Versus-Host Disease | Dec 2027 |
| Astellas | Gilteritinib Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor | FLT3, AXL | Phase 1 | Acute Myeloid Leukemia (AML); Non-small Cell Lung Cancer (NSCLC); AML (Acute Myeloid Leukemia); Acute Myeloid Leukemia … | Jul 2028 |
Acute Myeloid Leukemia (7) Acute Myeloid Leukemia (AML) (3) Acute Myeloid Leukemia With FLT3/ITD Mutation (2) Differentiated Thyroid Carcinoma (1) Unresectable or Metastatic Melanoma (1) Advanced Renal Cell Carcinoma (1) Borderline Resectable Pancreatic Ductal Adenocarcinoma (1) Non-small Cell Lung Cancer (NSCLC) (1) AML (Acute Myeloid Leukemia) (1) AML, Adult (1) AML (1) AML - Acute Myeloid Leukemia (1)
small molecule (4), mixed (2)
Beijing Scitech-Mq Pharmaceuticals (1) Jonsson Comprehensive Cancer Center (1) Astellas (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) Qurient (1) Xuanzhu Biopharmaceutical (1)
VEGFR2 (1) MET (1) PDGFRA (1) RET (1) FLT3 (1) MER (1) CSF1R (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.